Collaborations
Joining forces to accelerate our progress
Partnering to advance
our understanding
Our success to date is largely due to collaborations with other organisations spanning a variety of fields and countries. Achieving our long-term vision and commercial goals will require further alliances and we’re always keen to consider new partnerships with pharmaceutical companies active in the field of neurodegeneration.
Our focus on the tau pathology of neurodegenerative disease has generated a rich portfolio of patents and patent applications which we believe amounts to a strong intellectual property position. This consists of 836 granted patents and 120 pending, covering both product and method of use.
TauRx today
Our product, HMTM, is the first tau aggregate inhibitor (TAI) to be tested in late-stage clinical trials and its Phase III programme leads the field in therapeutics of pathological protein aggregation. The completed trials have substantially de-risked the programme, and conclusively show that our compound has clinically meaningful pharmacological activity on brain structure and function in two distinct diseases. We are now aiming to bring the first new treatment targeting pathological tau protein aggregation to market.
To discuss how you can help us change the lives of millions of people around the world, get in touch today.
someone in the world will develop dementia
